Safety of Tirofiban in acute ischemic stroke: the SaTIS trial

Background and Purpose: Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials. Safety and ef...

Full description

Bibliographic Details

Main Authors:	Siebler, Mario (Author) , Hennerici, Michael G. (Author) , Schneider, Dietmar (Author) , Reutern, Gerhard M. von (Author) , Seitz, Rüdiger J. (Author) , Röther, Joachim (Author) , Witte, Otto W. (Author) , Hamann, Gerhard (Author) , Junghans, Ulrich (Author) , Villringer, Arno (Author) , Fiebach, Jochen B. (Author)
Format:	Article (Journal)
Language:	English
Published:	[September 2011]
In:	Stroke Year: 2011, Volume: 42, Issue: 9, Pages: 2388-2392
ISSN:	1524-4628
DOI:	10.1161/STROKEAHA.110.599662
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.110.599662 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/STROKEAHA.110.599662
Author Notes:	Mario Siebler, Michael G. Hennerici, Dietmar Schneider, Gerhard M. von Reutern, Rüdiger J. Seitz, Joachim Röther, Otto W. Witte, Gerhard Hamann, Ulrich Junghans, Arno Villringer, Jochen B. Fiebach